Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity

References

• Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022 Sep;72(5):409–15. doi:10.3322/caac.21731.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, Chen X, Jiang X, McCall SJ, Inman BA, et al. Pre-existing castration-resistant prostate cancer–like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol. 2022 May;81(5):446–455. doi:10.1016/j.eururo.2021.12.039.
   PubMed Web of Science ®Google Scholar
• Bright RK, Bright JD, Byrne JA. Overexpressed oncogenic tumor-self antigens. Hum Vaccin Immunother. 2014;10(11):3297–3305. doi:10.4161/hv.29475.
   PubMed Web of Science ®Google Scholar
• Rausch S, Schwentner C, Stenzl A, Bedke J. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother. 2014;10(11):3146–3152. doi:10.4161/hv.29553.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411–422. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021 Sep 16;385(12):1091–1103. doi:10.1056/NEJMoa2107322.
   PubMed Web of Science ®Google Scholar
• Lopez-Bujanda ZA, Obradovic A, Nirschl TR, Crowley L, Macedo R, Papachristodoulou A, O’Donnell T, Laserson U, Zarif JC, Reshef R, et al. TGM4: an immunogenic prostate-restricted antigen. J Immunother Cancer. 2021 June;9(6):e001649. doi:10.1136/jitc-2020-001649.
   PubMed Web of Science ®Google Scholar
• Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, Shi Y, Sadtler K, Gao W, Lin J, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019 Oct;37(10):1174–1185. doi:10.1038/s41587-019-0247-3.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020 Jan;20(1):7–24. doi:10.1038/s41577-019-0210-z.
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020 Sep;585(7823):107–112. doi:10.1038/s41586-020-2537-9.
   PubMed Web of Science ®Google Scholar
• Paston SJ, Brentville VA, Symonds P, Durrant LG. Cancer vaccines, adjuvants, and delivery systems. Front Immunol. 2021;12:627932. doi:10.3389/fimmu.2021.627932.
   PubMed Web of Science ®Google Scholar
• Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021 Feb;52:101481. doi:10.1016/j.smim.2021.101481.
   PubMed Web of Science ®Google Scholar
• Brandum EP, Jørgensen AS, Rosenkilde MM, Hjortø GM. Dendritic cells and CCR7 expression: an important factor for autoimmune diseases, chronic inflammation, and cancer. Int J Mol Sci. 2021 Aug 3;22(15):8340. doi:10.3390/ijms22158340.
   PubMed Web of Science ®Google Scholar
• Salem A, Alotaibi M, Mroueh R, Basheer HA, Afarinkia K. CCR7 as a therapeutic target in cancer. Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188499. doi:10.1016/j.bbcan.2020.188499.
   PubMed Web of Science ®Google Scholar
• Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunological Rev. 2009 May;229(1):192–215. doi:10.1111/j.1600-065X.2009.00765.x.
   PubMedGoogle Scholar
• Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B. 2020;10(3):414–433. doi:10.1016/j.apsb.2019.08.010.
   PubMed Web of Science ®Google Scholar
• Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A, et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021 Sep 8;13(610):eabc7804. doi:10.1126/scitranslmed.abc7804.
   PubMed Web of Science ®Google Scholar
• Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) combination vaccine improves T-cell priming and enhances immunity, memory, and tumor elimination. Cancer Immunol Res. 2016 Sep 2;4(9):766–778. doi:10.1158/2326-6066.CIR-15-0228.
   PubMed Web of Science ®Google Scholar
• Xu Y, Hu Y, Xia H, Zhang S, Lei H, Yan B, Xiao ZX, Chen J, Pang J, Zha G-F. Delivery of mRNA vaccine with 1, 2-diesters-derived lipids elicits fast liver clearance for safe and effective cancer immunotherapy. Adv Healthc Mater. 2023 Nov 21;13(5):e2302691. doi:10.1002/adhm.202302691.
   PubMed Web of Science ®Google Scholar
• Sauter M, Sauter RJ, Nording H, Olbrich M, Emschermann F, Langer HF. Protocol to isolate and analyze mouse bone marrow derived dendritic cells (BMDC). STAR Protoc. 2022 Sep 16;3(3):101664. doi:10.1016/j.xpro.2022.101664.
   PubMedGoogle Scholar
• Lu T, Qian L, Xie Y, Zhang Q, Liu W, Ge W, Zhu Y, Ma L, Zhang C, Guo T, et al. Tissue-characteristic expression of mouse proteome. Mole Cell Proteomics: MCP. 2022 Oct;21(10):100408. doi:10.1016/j.mcpro.2022.100408.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Qi Y, Wang M, Yu N, Nan F, Zhang H, Tian M, Li C, Lu H, Jin N. mRNA vaccines encoding the HA protein of influenza a H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice. Vaccines (Basel). 2020 Mar 10;8(1):123. doi:10.3390/vaccines8010123.
   PubMed Web of Science ®Google Scholar
• Xu J, Lv J, Zhuang Q, Yang Z, Cao Z, Xu L, Pei P, Wang C, Wu H, Dong Z, et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat Nanotechnol. 2020 Dec;15(12):1043–1052. doi:10.1038/s41565-020-00781-4.
   PubMed Web of Science ®Google Scholar
• Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I, Allan RS, Wojtasiak M, Shortman K, Carbone FR, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol. 2009 May;10(5):488–495. doi:10.1038/ni.1724.
   PubMed Web of Science ®Google Scholar
• Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther. 2004 Oct;11(10):665–680. doi:10.1038/sj.cgt.7700741.
   PubMed Web of Science ®Google Scholar
• Saxena M, van der Burg SH, Melief CJM, Bhardwaj N, van der Burg SH. Therapeutic cancer vaccines. Nat Rev Cancer. 2021 June;21(6):360–378. doi:10.1038/s41568-021-00346-0.
   PubMed Web of Science ®Google Scholar
• Brina D, Ponzoni A, Troiani M, Calì B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D’Ambrosio M, Colucci M, et al. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells. Nat Cancer. 2023 Aug;4(8):1102–1121. doi:10.1038/s43018-023-00594-z.
   PubMedGoogle Scholar
• Liu Q, Sun Z, Chen L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell. 2020 Aug;11(8):549–564. doi:10.1007/s13238-020-00707-9.
   PubMed Web of Science ®Google Scholar
• Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015 Jun;15(6):388–400. doi:10.1038/nri3839.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O’Brien SA, He Y, Wang L, Zhang Q, Kim A, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell Apr. 2020 16;181(2):442–459.e29. doi:10.1016/j.cell.2020.03.048.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Sig Transduct Target Ther. 2021 Jul 12;6(1):263. doi:10.1038/s41392-021-00658-5.
   PubMed Web of Science ®Google Scholar
• Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019 Jan 27;70(1):479–499. doi:10.1146/annurev-med-051517-011947.
   PubMedGoogle Scholar
• Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 Trial. Cancer Cell. 2020 Oct 12;38(4):489–499.e3. doi:10.1016/j.ccell.2020.08.007.
   PubMed Web of Science ®Google Scholar
• Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, Goyvaerts C, Du Four S, Van der Jeught K, Bialkowski L, et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res. 2016 Feb;4(2):146–156. doi:10.1158/2326-6066.CIR-15-0163.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, et al. Final analysis of the ipilimumab versus placebo following radiotherapy Phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol. 2020 Dec;78(6):822–830. doi:10.1016/j.eururo.2020.07.032.
   PubMed Web of Science ®Google Scholar
• Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013 Oct 15;19(20):5626–5635. doi:10.1158/1078-0432.CCR-13-0545.
   PubMed Web of Science ®Google Scholar